(Reuters) – British American Tobacco, the maker of Dunhill and Lucky Strike cigarettes, said on Wednesday its COVID-19 vaccine candidate was approved by the U.S. Food and Drug Administration for Phase I human study.
The World’s No.2 cigarette company had earlier this year said it was working on a COVID-19 vaccine using proteins extracted from tobacco leaves.
The company said the enrolment for the study is expected to begin shortly.
(Reporting by Indranil Sarkar in Bengaluru; Editing by Arun Koyyur)
